Intuitive said the FDA has cleared its da Vinci 5 system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization.
Cardiac surgery was the first specialty cleared on the original da Vinci System in 2002. Since then, more than 140,000 robotic-assisted cardiac procedures have been performed using da Vinci systems across 51 countries.
The design of da Vinci 5 can support minimally invasive cardiac procedures by enabling surgeons to operate through small incisions without opening the breastbone. The system offers:
- 10,000x computing power for future innovation and digital solutions.
- Smart instrumentation capturing 1,000+ data points per second.
- Advanced imaging for enhanced visualization of vessels and perfusion.
- An integrated digital ecosystem supporting the complete journey from pre-operative planning through post-operative analytics.
To support adoption of cardiac surgery with da Vinci 5, Intuitive has established a dedicated team focused on building infrastructure, including the development of bespoke training programs, clinical evidence generation, and cardiac-specific instruments and accessories. A limited number of U.S. sites will begin working with Intuitive through 2026 to establish da Vinci 5 cardiac programs.
Da Vinci 5 is now indicated for the following selected thoracoscopically-assisted cardiac surgical procedures using non-force feedback instruments:
- Mitral valve repair
- IMA mobilization for cardiac revascularization
- Patent foramen ovale closure
- Atrial septal defect repair
- Left atrial appendage closure/occlusion
- Atrial myxoma excision
- Mitral valve replacement
- Tricuspid valve repair
- Epicardial pacing lead placement
